Cargando…
Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
INTRODUCTION: To compare the cost-effectiveness of vedolizumab with that of conventional therapy in patients with moderate-to-severe active Crohn’s disease (CD) in China. METHODS: A decision tree and Markov model were built to predict the lifetime cost and health outcomes in the induction phase and...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342392/ https://www.ncbi.nlm.nih.gov/pubmed/34089502 http://dx.doi.org/10.1007/s12325-021-01806-7 |